The biology and chemistry of hyperlipidemia

被引：260

作者：

Jain, Kishor S.

Kathiravan, M. K.

Somani, Rahul S.

Shishoo, Chamanlal J.

机构：

[1] Sinhgad Coll Pharm, Pune 411041, Maharashtra, India

[2] Poona Coll Pharm, Pune 411038, Maharashtra, India

[3] LM Coll Pharm, Ahmadabad 380009, Gujarat, India

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2007年 / 15卷 / 14期

关键词：

cholesterol; lipoproteins; atherosclerosis; antiatherogenic; oxidation; squalene synthase; squalene epoxidase; statins; co-enzyme Q10;

D O I：

10.1016/j.bmc.2007.04.031

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Coronary arterial diseases are responsible for more deaths than all other associated causes combined. Elevated serum cholesterol levels leading to atherosclerosis can cause coronary heart disease (CHD). Reduction in serum cholesterol levels reduces the risk for CHD, substantially. Medicinal chemists all around the world have been designing, synthesizing, and evaluating a variety of new bioactive molecules for lowering lipid levels. This review summarizes the disorders associated with elevation of lipids in blood and the current strategies to control them. The emphasis has been laid in particular on the new potential biological targets and the possible treatments as well as the current ongoing research status in the field of lipid lowering agents. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：4674 / 4699

页数：26

共 155 条

[1]

ADAMS JL, 1990, ABSTR 199 ACS M MEDI, P10

[2]

AITHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558

[3]

REDUCTION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE, APOLIPOPROTEIN D AND THE LP(A) LIPOPROTEIN WITH THE ANABOLIC-STEROID STANOZOLOL [J].